FluoroPharma Medical (FluoroPharma Medical) Buyback Yield % : 0.00 (As of Apr. 27, 2024)

View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

FluoroPharma Medical's current buyback yield was 0.00%.

FluoroPharma Medical Buyback Yield % Historical Data

The historical data trend for FluoroPharma Medical's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Buyback Yield % Chart

FluoroPharma Medical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Buyback Yield %

Get a 7-Day Free Trial

-6.91

-3.49

-1.74

FluoroPharma Medical Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of FluoroPharma Medical's Buyback Yield %

For the Biotechnology subindustry, FluoroPharma Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FluoroPharma Medical's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Buyback Yield % falls into.

FluoroPharma Medical Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

FluoroPharma Medical's Buyback Yield for the fiscal year that ended in Dec. 2016 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	3.748173
	=	0.00%

FluoroPharma Medical's annualized Buyback Yield for the quarter that ended in Dec. 2016 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	3.748173
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2016) data.

FluoroPharma Medical Buyback Yield % Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

FluoroPharma Medical (FluoroPharma Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042

Website

http://www.fluoropharma.com

FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.

Executives

Johan M. Spoor

director, officer: CEO, PRESIDENT, CHAIRMAN

500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus

FPMI Restructures CardioPET License With Massachusetts General Hospital

By Marketwired Marketwired • 09-27-2018